Pharma’s UK dissatisfaction mounts as Merck & Co axes $1.3bn expansion
Biotech and research investments from Lilly and AstraZeneca also put on hold as pricing row rumbles on.
List view / Grid view
Biotech and research investments from Lilly and AstraZeneca also put on hold as pricing row rumbles on.
The novel approach could enhance quality testing applications in pharmaceutical manufacturing.
The company’s CEO says the shift will help prioritise investment into obesity and diabetes, the company’s leading therapy areas.
The innovation is set to change how eligible bladder cancer patients in the US are treated who are unresponsive to traditional therapy.
Gains access to potential breakthrough atherosclerotic cardiovascular disease biologic therapy pacibekitug.
As an important policy tool, the new editions by the WHO mark a “significant” step in broadening access to new medicines with proven clinical benefits.
Deal with Kaerus Bioscience for KER-0193 could be worth $450m to the UK-based biotech.
The regulator’s new principles aim to ease the pathway to regulatory approval for rare disease drug developers in the US.
CE mark for Contivue platform supports its ambitions for Susvimo in age-related macular degeneration (AMD).
Significant investment in advanced technologies Is expected to support global adoption of mass spectrometry in the next five years.
European Parliament's SANT Committee urges for greater control on medicine provisions to help strengthen security of supply.
First-of-its-kind case continues EMA and MHRA harmonisation, streamlining the global biosimilar approval pathway.
2 September 2025 | By FUJIFILM Wako Europe GmbH
Join this webinar to find out how RT-rt PCR is revolutionising sterility testing and discover a unique approach that provides reliable one-day results and enhanced sensitivity and detection capabilities.
The first bispecific antibody drug conjugate market entrants are predicted to be in China or Japan as East Asia becomes a key battleground for local and multinational players.
And Eli Lilly and Company’s new oral GLP-1 obesity therapy orforglipron shines in late-phase clinical trials.